Loading
Depression / Sertraline 50 MG / Allopurinol 300 MG · Phase 2/3 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2/3 trial evaluating allopurinol 300 mg as an adjunct to sertraline in major depressive disorder, with the primary endpoint of change in Ham-D depression score at 8 weeks. No results have been posted; the trial is currently recruiting. The rationale rests on the hypothesis that a dual-mechanism strategy may benefit treatment-resistant patients, but efficacy and safety remain untested in this population.
Phase 2/3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Depression; age from 18 Years; to 60 Years. Intervention: Control group; Allopurinol group. Compared with: Sertraline 50 mg (implied; not explicitly stated as comparator in registry record). n = 70. 1 site: Egypt.
This is a planned Phase 2/3 trial evaluating allopurinol 300 mg as an adjunct to sertraline in major depressive disorder, with the primary endpoint of change in Ham-D depression score at 8 weeks. No results have been posted; the trial is currently recruiting. The rationale rests on the hypothesis that a dual-mechanism strategy may benefit treatment-resistant patients, but efficacy and safety remain untested in this population.
This is a registry record with no posted results; efficacy and safety cannot be assessed.
The source did not state who this applies to in practice.
This is an active, unpublished trial registration examining an exploratory combination strategy (allopurinol plus sertraline) for depression; no results are reported and the design is early-phase Phase 2/3.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07574060). This is a study registration, not published results. Lead sponsor: Tanta University. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 70 participants (ESTIMATED). Conditions: Depression. Interventions: DRUG: Sertraline 50 MG; DRUG: Allopurinol 300 MG. Primary outcome measures: Change in the 17-item Ham-D depression score. , 8 weeks. Brief summary: Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.